IN165717B
(cs)
*
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
US5529932A
(en)
*
|
1988-01-28 |
1996-06-25 |
Pharmacia, S.P.A. |
Isolated DNA encoding a plant ribosome inactivating protein from the leaves of saponaria officinalis
|
IL89220A
(en)
*
|
1988-02-11 |
1994-02-27 |
Bristol Myers Squibb Co |
Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them
|
DE4004573A1
(de)
*
|
1989-02-17 |
1990-08-23 |
Tanabe Seiyaku Co |
Neues versuchstier und seine herstellung
|
US5354844A
(en)
*
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
US5191067A
(en)
*
|
1989-04-27 |
1993-03-02 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
US5576288A
(en)
*
|
1989-04-27 |
1996-11-19 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
DE69018226T2
(de)
*
|
1989-07-20 |
1995-09-21 |
Sandoz-Patent-Gmbh, 79539 Loerrach |
Markierte polypeptidderivate.
|
US5208323A
(en)
*
|
1989-08-10 |
1993-05-04 |
Universite Laval |
Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US5632988A
(en)
*
|
1989-10-23 |
1997-05-27 |
Schering Corporation |
Polypeptide inhibitors of gamma interferon
|
ATE200493T1
(de)
*
|
1990-03-02 |
2001-04-15 |
Boston Medical Ct Corp |
Verbesserte chimäre toxine
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US5137877B1
(en)
*
|
1990-05-14 |
1996-01-30 |
Bristol Myers Squibb Co |
Bifunctional linking compounds conjugates and methods for their production
|
DE59103985D1
(en)
*
|
1990-05-30 |
1995-02-02 |
Deutsches Krebsforsch |
Polyethersubstituierte tumormittel.
|
IL98528A0
(en)
*
|
1990-06-21 |
1992-07-15 |
Merck & Co Inc |
Pharmaceutical compositions containing hybrid for killing bladder cancer cells
|
AU657910B2
(en)
*
|
1990-07-05 |
1995-03-30 |
Akzo N.V. |
Receptor directed-toxin conjugates
|
US5478804A
(en)
*
|
1990-09-19 |
1995-12-26 |
The Salk Institute For Biological Studies |
Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
|
AU8730691A
(en)
*
|
1990-09-28 |
1992-04-28 |
Neorx Corporation |
Polymeric carriers for release of covalently linked agents
|
US5431899A
(en)
*
|
1991-02-04 |
1995-07-11 |
University Of Saskatchewan |
Rotavirus VP6 as a diagnostic and targeting agent
|
US5464753A
(en)
*
|
1991-03-08 |
1995-11-07 |
Univ Illinois |
Purification and manipulation of bone marrow and blood cells on the basis of P-glycoprotein expression
|
WO1992016221A1
(en)
*
|
1991-03-15 |
1992-10-01 |
Synergen, Inc. |
Pegylation of polypeptides
|
AU662155B2
(en)
*
|
1991-05-10 |
1995-08-24 |
Celtrix Pharmaceuticals, Inc. |
Targeted delivery of bone growth factors
|
ES2075402T3
(es)
*
|
1991-07-22 |
1995-10-01 |
Bracco Int Bv |
Conjugados quelados con metales paramagneticos para enfoque deliberado.
|
US5981273A
(en)
*
|
1991-09-30 |
1999-11-09 |
Boehringer Ingelheim Int'l. Gmbh |
Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
|
NZ244306A
(en)
*
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
US5521291A
(en)
*
|
1991-09-30 |
1996-05-28 |
Boehringer Ingelheim International, Gmbh |
Conjugates for introducing nucleic acid into higher eucaryotic cells
|
US5922859A
(en)
*
|
1992-02-01 |
1999-07-13 |
Boehringer Ingelheim International Gmbh |
Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
|
CA2076465C
(en)
*
|
1992-03-25 |
2002-11-26 |
Ravi V. J. Chari |
Cell binding agent conjugates of analogues and derivatives of cc-1065
|
EP0643584B1
(en)
*
|
1992-05-28 |
2000-03-15 |
The University Of Toledo |
Delivery of a cytotoxic compound to a cancer cell using a pathway of plasminogen activator material
|
US5679350A
(en)
*
|
1992-05-28 |
1997-10-21 |
The University Of Toledo |
Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
|
AU685058B2
(en)
*
|
1992-06-16 |
1998-01-15 |
Selective Genetics, Inc. |
Recombinant production of saporin-containing proteins
|
US5393737A
(en)
*
|
1992-08-20 |
1995-02-28 |
Health Research, Inc. |
Cytotoxic drug conjugates for treatment of neoplastic diseases
|
DK0662146T3
(da)
*
|
1992-09-03 |
2000-11-13 |
Univ California |
Dorsalvævpåvirkende faktor og præparat
|
US5466672A
(en)
*
|
1992-12-04 |
1995-11-14 |
Ophidian Pharmaceuticals, Inc. |
Therapeutic use of clostridium difficile toxin A
|
DE69423753T2
(de)
|
1993-05-05 |
2000-11-02 |
Keith Rose |
Polyoximverbindungen und deren herstellung
|
US6001364A
(en)
|
1993-05-05 |
1999-12-14 |
Gryphon Sciences |
Hetero-polyoxime compounds and their preparation by parallel assembly
|
US6174530B1
(en)
|
1993-05-05 |
2001-01-16 |
Gryphon Sciences |
Homogeneous polyoxime compositions and their preparation by parallel assembly
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US5502037A
(en)
*
|
1993-07-09 |
1996-03-26 |
Neuromed Technologies, Inc. |
Pro-cytotoxic drug conjugates for anticancer therapy
|
US6491905B1
(en)
*
|
1993-09-14 |
2002-12-10 |
The Uab Research Foundation |
Recombinant bacterial cells for delivery of PNP to tumor cells
|
DK0648503T3
(da)
*
|
1993-09-22 |
2000-10-02 |
Hoechst Ag |
Pro-prodrugs, deres fremstilling og anvendelse
|
US7097839B1
(en)
*
|
1993-10-26 |
2006-08-29 |
Thomas Jefferson University |
ST receptor binding compounds and methods of using the same
|
US5879656A
(en)
*
|
1993-10-26 |
1999-03-09 |
Thomas Jefferson University |
Methods of treating metastatic colorectal cancer with ST receptor binding compounds
|
US5962220A
(en)
*
|
1993-10-26 |
1999-10-05 |
Thomas Jefferson University |
Compositions that specifically bind to colorectal cells and methods of using the same
|
EP0657175B1
(en)
*
|
1993-12-09 |
2005-03-02 |
Centro de Inmunologia Molecular |
Vaccine comprising human autologous epidermal growth factor and use thereof
|
US6551618B2
(en)
*
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
US5911995A
(en)
*
|
1994-08-19 |
1999-06-15 |
Regents Of The University Of Minnesota |
EGF-genistein conjugates for the treatment of cancer
|
US5587459A
(en)
*
|
1994-08-19 |
1996-12-24 |
Regents Of The University Of Minnesota |
Immunoconjugates comprising tyrosine kinase inhibitors
|
DE4433890C2
(de)
*
|
1994-09-22 |
1999-02-18 |
Deutsches Krebsforsch |
Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein
|
ATE232089T1
(de)
*
|
1994-11-10 |
2003-02-15 |
Univ Kentucky Res Found |
Implantierbare wiederauffüllbare vorrichtung mit gesteuerter freisetzung zur verabreichung von arzneistoffen unmittelbar an einen inneren teil des körpers
|
US5766899A
(en)
*
|
1995-02-27 |
1998-06-16 |
Board Of Regents , The University Of Texas System |
Targeted nucleic acid delivery into liver cells
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US20030119724A1
(en)
*
|
1995-11-22 |
2003-06-26 |
Ts`O Paul O.P. |
Ligands to enhance cellular uptake of biomolecules
|
PT871490E
(pt)
*
|
1995-12-22 |
2003-07-31 |
Bristol Myers Squibb Co |
Ligantes de hidrazona ramificada
|
US20050025740A1
(en)
*
|
1996-01-05 |
2005-02-03 |
Keith Rose |
Polyoxime compounds and their preparation
|
KR100561788B1
(ko)
|
1996-03-12 |
2006-09-20 |
피지-티엑스엘 컴파니,엘.피. |
수용성파클리탁셀전구약물을포함하는조성물및이러한조성물을포함하는이식가능한의료장치
|
US6441025B2
(en)
*
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
US6030941A
(en)
*
|
1996-05-01 |
2000-02-29 |
Avi Biopharma, Inc. |
Polymer composition for delivering substances in living organisms
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
US5952294A
(en)
*
|
1996-07-31 |
1999-09-14 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Peptidyl prodrugs and methods of making and using the same
|
DE19636889A1
(de)
|
1996-09-11 |
1998-03-12 |
Felix Dr Kratz |
Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
|
US6080383A
(en)
*
|
1997-01-13 |
2000-06-27 |
Rose; Samuel |
Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
|
AU7124598A
(en)
*
|
1997-04-18 |
1998-11-13 |
Access Pharmaceuticals, Inc. |
Polymer-platinum compounds
|
US5965118A
(en)
*
|
1997-04-18 |
1999-10-12 |
Access Pharmaceuticals, Inc. |
Polymer-platinum compounds
|
US6548482B1
(en)
|
1997-05-05 |
2003-04-15 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
EP0981545B1
(en)
*
|
1997-05-05 |
2006-09-13 |
Mayo Foundation For Medical Education And Research |
IGFIIE/ IGFBP2 complex
|
US6916790B2
(en)
|
1997-05-05 |
2005-07-12 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
US6030997A
(en)
*
|
1998-01-21 |
2000-02-29 |
Eilat; Eran |
Acid labile prodrugs
|
US6866837B2
(en)
|
1998-06-05 |
2005-03-15 |
Mallinckrodt Inc. |
Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors
|
US6747055B1
(en)
*
|
1998-07-17 |
2004-06-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Water-soluble drugs and methods for their production
|
EP1098666B1
(en)
*
|
1998-07-17 |
2013-01-16 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Water-soluble drugs and methods for their production
|
GB9904582D0
(en)
*
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
US7018654B2
(en)
*
|
1999-03-05 |
2006-03-28 |
New River Pharmaceuticals Inc. |
Pharmaceutical composition containing an active agent in an amino acid copolymer structure
|
US7060708B2
(en)
*
|
1999-03-10 |
2006-06-13 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US6716452B1
(en)
*
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US20010041189A1
(en)
*
|
1999-04-13 |
2001-11-15 |
Jingya Xu |
Poly(dipeptide) as a drug carrier
|
US6706892B1
(en)
*
|
1999-09-07 |
2004-03-16 |
Conjuchem, Inc. |
Pulmonary delivery for bioconjugation
|
US20030054977A1
(en)
*
|
1999-10-12 |
2003-03-20 |
Cell Therapeutics, Inc. |
Manufacture of polyglutamate-therapeutic agent conjugates
|
US7067111B1
(en)
*
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
US20020077290A1
(en)
*
|
2000-03-17 |
2002-06-20 |
Rama Bhatt |
Polyglutamic acid-camptothecin conjugates and methods of preparation
|
DE60142228D1
(de)
|
2000-03-27 |
2010-07-08 |
Univ Jefferson |
Zusammensetzungen und methoden zur identifizierung und zum targeting von krebszellen aus dem verdauungskanal
|
BRPI0111220B8
(pt)
*
|
2000-06-02 |
2021-07-27 |
Univ Texas |
conjugados de fármacos com etilenodicisteína (ec)
|
JP2004501664A
(ja)
*
|
2000-06-30 |
2004-01-22 |
ボード・オブ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム |
標的化薬剤送達のための腫瘍組織を浸潤する細胞特異的な内部移行ペプチドの単離
|
US20020099013A1
(en)
*
|
2000-11-14 |
2002-07-25 |
Thomas Piccariello |
Active agent delivery systems and methods for protecting and administering active agents
|
US7163918B2
(en)
|
2000-08-22 |
2007-01-16 |
New River Pharmaceuticals Inc. |
Iodothyronine compositions
|
BR0114713A
(pt)
*
|
2000-10-16 |
2004-01-13 |
Neopharm Inc |
Formulação lipossÈmica de mitoxantrona
|
US8394813B2
(en)
*
|
2000-11-14 |
2013-03-12 |
Shire Llc |
Active agent delivery systems and methods for protecting and administering active agents
|
EP1355672A2
(en)
|
2000-12-01 |
2003-10-29 |
Cell Works Inc. |
Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use
|
CU22999A1
(es)
|
2001-12-04 |
2004-10-12 |
Centro Inmunologia Molecular |
Método de tratamiento de enfermedades malignas e infecciosas crónicas
|
EP1389090A2
(en)
*
|
2001-04-26 |
2004-02-18 |
Board of Regents, The University of Texas System |
Diagnostic imaging compositions, their methods of synthesis and use
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
EP1392359B2
(en)
|
2001-05-11 |
2013-03-13 |
Ludwig Institute for Cancer Research Ltd. |
Specific binding proteins and uses thereof
|
EP1395273B1
(en)
*
|
2001-05-15 |
2006-07-19 |
Faulk Pharmaceuticals, Inc. |
Targeted delivery of drugs for the treatment of viral infections
|
WO2002094271A1
(en)
*
|
2001-05-15 |
2002-11-28 |
Faulk Pharmaceuticals, Inc. |
Targeted delivery of bioaffecting compounds for the treatment of cancer
|
US7067494B2
(en)
*
|
2001-06-22 |
2006-06-27 |
The University Of British Columbia |
Antimitotic eleuthesides
|
US7375082B2
(en)
*
|
2002-02-22 |
2008-05-20 |
Shire Llc |
Abuse-resistant hydrocodone compounds
|
US7169752B2
(en)
*
|
2003-09-30 |
2007-01-30 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US20060014697A1
(en)
*
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
US7338939B2
(en)
*
|
2003-09-30 |
2008-03-04 |
New River Pharmaceuticals Inc. |
Abuse-resistant hydrocodone compounds
|
US20070066537A1
(en)
*
|
2002-02-22 |
2007-03-22 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US7375083B2
(en)
*
|
2003-09-30 |
2008-05-20 |
Shire Llc |
Pharmaceutical compositions for prevention of overdose or abuse
|
US20030109432A1
(en)
*
|
2001-12-10 |
2003-06-12 |
Zuo William W. |
Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same
|
US7261875B2
(en)
*
|
2001-12-21 |
2007-08-28 |
Board Of Regents, The University Of Texas System |
Dendritic poly (amino acid) carriers and methods of use
|
RU2196604C1
(ru)
*
|
2001-12-21 |
2003-01-20 |
Северин Евгений Сергеевич |
Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
|
US7659253B2
(en)
*
|
2002-02-22 |
2010-02-09 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
AU2003213259C1
(en)
*
|
2002-02-22 |
2009-07-16 |
Shire Llc |
Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels
|
IL163667A0
(en)
*
|
2002-02-22 |
2005-12-18 |
New River Pharmaceuticals Inc |
Novel sustained release pharmaceutical compounds to preventabuse of controlled substances
|
US7105486B2
(en)
*
|
2002-02-22 |
2006-09-12 |
New River Pharmaceuticals Inc. |
Abuse-resistant amphetamine compounds
|
AU2003217676B2
(en)
|
2002-02-22 |
2009-06-11 |
Takeda Pharmaceutical Company Limited |
Active agent delivery systems and methods for protecting and administering active agents
|
US7700561B2
(en)
*
|
2002-02-22 |
2010-04-20 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
SI1551372T1
(en)
|
2002-09-20 |
2018-08-31 |
Alpharma Pharmaceuticals Llc |
SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
|
CA2505537A1
(en)
*
|
2002-11-07 |
2004-05-27 |
Board Of Regents, The University Of Texas System |
Ethylenedicysteine (ec)-drug conjugates, compositions and methods for tissue specific disease imaging
|
US7981667B2
(en)
*
|
2003-05-07 |
2011-07-19 |
Indiana University Research And Technology Corporation |
Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto
|
KR101159477B1
(ko)
*
|
2003-05-29 |
2012-07-02 |
샤이어 엘엘씨 |
남용 방지성 암페타민 화합물
|
WO2005016368A2
(en)
*
|
2003-08-19 |
2005-02-24 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of phosphophoryn for inducing biomineralization and bone regeneration
|
EP1675857B1
(en)
|
2003-10-22 |
2011-07-13 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
|
US20120095058A1
(en)
|
2003-12-03 |
2012-04-19 |
Hanauske-Abel H M |
Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
PT1695991E
(pt)
*
|
2003-12-10 |
2010-03-02 |
Toudai Tlo Ltd |
Complexo de coordenação de diaminociclohexano platina (ii) com copolímero de bloco contendo segmento poli(ácido carboxílico) e agente antitumoral compreendendo o mesmo
|
HUE037549T2
(hu)
|
2004-04-07 |
2018-09-28 |
Rinat Neuroscience Corp |
Eljárások csontrákfájdalom kezelésére idegi növekedési faktor antagonista antitest beadásával
|
US8454927B2
(en)
*
|
2004-08-04 |
2013-06-04 |
Crystalplex Corporation |
Alloyed semiconductor nanocrystals
|
US20060036084A1
(en)
*
|
2004-08-04 |
2006-02-16 |
Lianhua Qu |
Conglomerated semiconductor nanocrystals
|
EP2474310B1
(en)
*
|
2005-06-09 |
2013-08-21 |
NanoCarrier Co., Ltd. |
Method for producing polymerized coordination compounds of platinum complex
|
WO2007055902A1
(en)
|
2005-11-03 |
2007-05-18 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Immunogenic peptides and methods of use for treating and preventing cancer
|
KR20080074207A
(ko)
*
|
2005-12-05 |
2008-08-12 |
닛토덴코 가부시키가이샤 |
폴리글루타메이트-아미노산 콘쥬게이트 및 이의 제조 방법
|
US7820174B2
(en)
|
2006-02-24 |
2010-10-26 |
The United States Of America As Represented By The Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
US9107863B2
(en)
*
|
2006-03-27 |
2015-08-18 |
The Buck Institute For Age Reasearch |
Reagents and methods for cancer treatment and prevention
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
DK2526932T3
(en)
|
2006-06-19 |
2017-07-17 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US8088379B2
(en)
*
|
2006-09-26 |
2012-01-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Modified T cell receptors and related materials and methods
|
US10925977B2
(en)
*
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
KR101563010B1
(ko)
|
2006-10-31 |
2015-10-26 |
더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 |
평활화 폴리펩티드 및 사용 방법
|
AU2008206442B2
(en)
|
2007-01-12 |
2012-10-18 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
gp100-specific T cell receptors and related materials and methods of use
|
US9090693B2
(en)
*
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
US20080181852A1
(en)
*
|
2007-01-29 |
2008-07-31 |
Nitto Denko Corporation |
Multi-functional Drug Carriers
|
US9023356B2
(en)
|
2007-03-15 |
2015-05-05 |
Ludwig Institute For Cancer Research Ltd |
Treatment method using EGFR antibodies and SRC inhibitors and related formulations
|
CN101674852A
(zh)
*
|
2007-04-10 |
2010-03-17 |
日东电工株式会社 |
多功能聚谷氨酸盐药物载体
|
US8197828B2
(en)
*
|
2007-05-09 |
2012-06-12 |
Nitto Denko Corporation |
Compositions that include a hydrophobic compound and a polyamino acid conjugate
|
CN101730549B
(zh)
*
|
2007-05-09 |
2015-12-09 |
日东电工株式会社 |
与铂类药物结合的聚合物
|
EP2155253A2
(en)
*
|
2007-05-09 |
2010-02-24 |
Nitto Denko Corporation |
Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
|
ES2609915T3
(es)
|
2007-08-14 |
2017-04-25 |
Ludwig Institute For Cancer Research Ltd. |
Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
|
CA2698094A1
(en)
*
|
2007-08-31 |
2009-03-05 |
The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services |
Compounds for inhibiting wip1, prodrugs and compositions thereof, and related methods
|
AU2009222230A1
(en)
*
|
2008-03-06 |
2009-09-11 |
Nitto Denko Corporation |
Polymer paclitaxel conjugates and methods for treating cancer
|
WO2010075417A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Survivin specific t cell receptor for treating cancer
|
WO2010075303A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
|
US8785601B2
(en)
|
2009-01-28 |
2014-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
US9616245B2
(en)
*
|
2009-03-16 |
2017-04-11 |
Rajah Vijay Kumar |
Method of treating cells with drug and radiation according to proton density
|
US8563513B2
(en)
|
2009-03-27 |
2013-10-22 |
Van Andel Research Institute |
Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
|
US9849146B2
(en)
|
2009-07-20 |
2017-12-26 |
Rutgers, The State University Of New Jersey |
Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
|
US8603814B2
(en)
*
|
2009-07-20 |
2013-12-10 |
Rutgers The State University Of New Jersey |
Method of inhibiting nonsense-mediated mRNA decay
|
WO2011032099A1
(en)
|
2009-09-11 |
2011-03-17 |
The Board Of Trustees Of The University Of Illinois |
Methods of treating diastolic dysfunction and related conditions
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
JP5934099B2
(ja)
|
2009-10-01 |
2016-06-15 |
アメリカ合衆国 |
抗血管内皮増殖因子受容体−2キメラ抗原受容体及び癌の治療のためのその使用
|
CN102666845B
(zh)
|
2009-10-16 |
2015-06-10 |
不列颠哥伦比亚大学 |
磷酸酶和张力蛋白同系物(pten)抑制剂组合物,用途以及方法
|
WO2011056572A1
(en)
|
2009-10-27 |
2011-05-12 |
The Board Of Trustees Of The University Of Illinois |
Methods of diagnosing diastolic dysfunction
|
CA2780572A1
(en)
|
2009-11-13 |
2011-05-19 |
The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services |
Modulated programmed death ligand-1
|
US8703701B2
(en)
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
CA2788304A1
(en)
|
2010-01-27 |
2011-08-04 |
Indiana University Research And Technology Corporation |
Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
|
ES2575160T3
(es)
|
2010-03-15 |
2016-06-24 |
The Board Of Trustees Of The University Of Illinois |
Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
|
ES2734889T3
(es)
|
2010-09-21 |
2019-12-12 |
Us Health |
Receptores de células T anti-SSX-2 y materiales relacionados y métodos de uso
|
WO2012054825A1
(en)
|
2010-10-22 |
2012-04-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mage-a3 t cell receptors and related materials and methods of use
|
US9029502B2
(en)
|
2010-12-20 |
2015-05-12 |
The Regents Of The University Of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
WO2012088116A2
(en)
|
2010-12-22 |
2012-06-28 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
CN102675422B
(zh)
|
2011-03-15 |
2014-02-05 |
天津托普泰克生物科技有限公司 |
抗乙型肝炎病毒x蛋白多肽药物
|
PT3459560T
(pt)
|
2011-04-08 |
2021-05-24 |
Us Health |
Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização dos mesmos para o tratamento de cancro
|
CN102746378B
(zh)
|
2011-04-22 |
2014-10-22 |
天津托普泰克生物科技有限公司 |
抗脂肪酸合成酶多肽及其应用
|
AU2012268013B2
(en)
|
2011-06-09 |
2016-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes
|
EP2723367B1
(en)
|
2011-06-22 |
2017-05-03 |
Indiana University Research and Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
CA2848209C
(en)
|
2011-09-15 |
2021-06-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
|
US9206240B2
(en)
|
2011-09-16 |
2015-12-08 |
The United States of America, as represented by the Secretary, Department of Helath and Human Services |
Pseudomonas exotoxin A with less immunogenic B cell epitopes
|
CA2851795C
(en)
|
2011-10-20 |
2018-11-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd22 chimeric antigen receptors
|
US8859491B2
(en)
|
2011-11-17 |
2014-10-14 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
|
CA3116051C
(en)
|
2012-03-23 |
2023-09-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
RU2766608C2
(ru)
|
2012-04-11 |
2022-03-15 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
|
PT2852613T
(pt)
|
2012-05-22 |
2019-05-20 |
Us Health |
Recetores de célula t anti-ny-eso-1 murinos
|
CN104619350A
(zh)
|
2012-06-14 |
2015-05-13 |
Ambrx公司 |
结合到核受体配体多肽的抗psma抗体
|
CA2877127A1
(en)
|
2012-06-21 |
2013-12-27 |
Indiana University Research And Technology Corporation |
Analogs of glucagon exhibiting gip receptor activity
|
JP6311708B2
(ja)
|
2012-06-21 |
2018-04-18 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
Gip受容体活性を示すグルカゴンアナローグ
|
EP3636665B1
(en)
|
2012-09-14 |
2022-06-29 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
T cell receptors recognizing mhc class ii-restricted mage-a3
|
BR112015009003B1
(pt)
|
2012-10-24 |
2023-01-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Receptores de antígeno quiméricos que se ligam especificamente a cd22, ácido nucleico, vetor de expressão recombinante, microrganismo transgênico, composição farmacêutica, e uso dos mesmos
|
US9790282B2
(en)
|
2013-03-25 |
2017-10-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
|
US9890369B2
(en)
|
2013-06-20 |
2018-02-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor
|
CN110511960B
(zh)
|
2013-07-15 |
2023-05-23 |
美国卫生和人力服务部 |
抗人乳头瘤病毒16 e6 t细胞受体
|
US9388222B2
(en)
|
2013-10-06 |
2016-07-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modified Pseudomonas exotoxin A
|
RU2701346C1
(ru)
|
2013-12-06 |
2019-09-25 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения
|
EP3647412A1
(en)
|
2014-04-23 |
2020-05-06 |
Juno Therapeutics, Inc. |
Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
|
EP3149031B1
(en)
|
2014-05-29 |
2019-12-18 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-human papillomavirus 16 e7 t cell receptors
|
KR102668549B1
(ko)
|
2014-06-02 |
2024-05-22 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
Cd19를 표적화하는 키메라 항원 수용체
|
MA40253A
(fr)
|
2014-07-15 |
2017-05-24 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
IL251774B
(en)
|
2014-10-20 |
2022-07-01 |
Juno Therapeutics Inc |
Methods and preparations for dosing in stress cell therapy
|
EP3215164A1
(en)
|
2014-11-03 |
2017-09-13 |
Immures S.r.l. |
T cell receptors
|
PT3757206T
(pt)
|
2014-11-05 |
2024-05-21 |
Juno Therapeutics Inc |
Métodos de transdução e processamento de células
|
KR20170087514A
(ko)
|
2014-12-03 |
2017-07-28 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료를 위한 방법 및 조성물
|
KR20170128234A
(ko)
|
2015-01-16 |
2017-11-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ror1에 특이적인 항체 및 키메라 항원 수용체
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
US20180161368A1
(en)
|
2015-05-29 |
2018-06-14 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
BR112018008111A2
(pt)
|
2015-10-22 |
2018-11-06 |
Juno Therapeutics Gmbh |
métodos, kits, agentes e aparelhos para transdução
|
US11020429B2
(en)
|
2015-11-05 |
2021-06-01 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
EP4212547A1
(en)
|
2015-12-03 |
2023-07-19 |
Juno Therapeutics, Inc. |
Modified chimeric receptors and related compositions and methods
|
WO2017096331A1
(en)
|
2015-12-04 |
2017-06-08 |
Juno Therapeutics, Inc. |
Methods and compositions related to toxicity associated with cell therapy
|
WO2017161212A1
(en)
|
2016-03-16 |
2017-09-21 |
Juno Therapeutics, Inc. |
Methods for adaptive design of a treatment regimen and related treatments
|
WO2017161208A1
(en)
|
2016-03-16 |
2017-09-21 |
Juno Therapeutics, Inc. |
Methods for determining dosing of a therapeutic agent and related treatments
|
CA3018588A1
(en)
|
2016-03-22 |
2017-09-28 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Early intervention methods to prevent or ameliorate toxicity
|
EP3452499A2
(en)
|
2016-05-06 |
2019-03-13 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
EP4011381A1
(en)
|
2016-06-03 |
2022-06-15 |
Memorial Sloan-Kettering Cancer Center |
Adoptive cell therapies as early treatment options
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
MA45455A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Procédé d'identification d'épitopes peptidiques, molécules qui se lient à de tels épitopes et utilisations associées
|
WO2018005759A1
(en)
|
2016-07-01 |
2018-01-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
|
CN110087672A
(zh)
|
2016-07-29 |
2019-08-02 |
朱诺治疗学股份有限公司 |
免疫调节多肽及相关组合物和方法
|
MX2019003768A
(es)
|
2016-10-03 |
2019-06-24 |
Juno Therapeutics Inc |
Moleculas de enlace especificas de hpv.
|
CA3045323A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
MX2019006286A
(es)
|
2016-12-03 |
2020-02-07 |
Juno Therapeutics Inc |
Metodos para determinar la dosificacion en la terapia celular.
|
BR112019011025A2
(pt)
|
2016-12-03 |
2019-10-08 |
Juno Therapeutics Inc |
métodos para modulação de células t car
|
CN110249046A
(zh)
|
2016-12-05 |
2019-09-17 |
朱诺治疗学股份有限公司 |
用于过继细胞疗法的工程化细胞的产生
|
CN110691792A
(zh)
|
2017-01-10 |
2020-01-14 |
朱诺治疗学股份有限公司 |
细胞疗法的表观遗传学分析及相关方法
|
US11517627B2
(en)
|
2017-01-20 |
2022-12-06 |
Juno Therapeutics Gmbh |
Cell surface conjugates and related cell compositions and methods
|
WO2018160622A1
(en)
|
2017-02-28 |
2018-09-07 |
Endocyte, Inc. |
Compositions and methods for car t cell therapy
|
CA3056261A1
(en)
|
2017-04-07 |
2018-10-11 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
MA49288A
(fr)
|
2017-04-27 |
2020-03-04 |
Juno Therapeutics Gmbh |
Reactifs particulaires oligomères et leurs méthodes d'utilisation
|
WO2018223101A1
(en)
|
2017-06-02 |
2018-12-06 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
MA48781A
(fr)
|
2017-06-02 |
2020-04-08 |
Juno Therapeutics Inc |
Articles de fabrication et procédés liés à la toxicité associée à la thérapie cellulaire
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
MX2020003536A
(es)
|
2017-10-03 |
2020-09-14 |
Juno Therapeutics Inc |
Moleculas de union especifica a virus de papiloma humano (hpv).
|
BR112020008323A2
(pt)
|
2017-11-01 |
2020-11-03 |
Juno Therapeutics Inc |
anticorpos e receptores de antígenos quiméricos específicos para antígeno de maturação de células b
|
US20210254000A1
(en)
|
2017-11-01 |
2021-08-19 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
CA3082010A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
|
CN111542596A
(zh)
|
2017-11-01 |
2020-08-14 |
朱诺治疗学股份有限公司 |
产生工程化细胞的治疗性组合物的方法
|
EP3704251A2
(en)
|
2017-11-01 |
2020-09-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
CN111556893A
(zh)
|
2017-11-06 |
2020-08-18 |
爱迪塔斯医药股份有限公司 |
免疫疗法t细胞中cblb的crispr-cas9编辑的方法、组合物和组分
|
MA51210A
(fr)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
Procédés de dosage et de modulation de cellules génétiquement modifiées
|
BR112020011215A2
(pt)
|
2017-12-08 |
2020-11-17 |
Juno Therapeutics Inc |
processo para a produção de uma composição de células t modificadas
|
AU2018379091A1
(en)
|
2017-12-08 |
2020-06-25 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
CN112203680A
(zh)
|
2017-12-08 |
2021-01-08 |
朱诺治疗学股份有限公司 |
用于细胞疗法的表型标记和相关方法
|
US12006356B2
(en)
|
2017-12-15 |
2024-06-11 |
Juno Therapeutics, Inc. |
Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
|
CN112055595A
(zh)
|
2018-01-22 |
2020-12-08 |
恩多塞特公司 |
Car t细胞的使用方法
|
WO2019152743A1
(en)
|
2018-01-31 |
2019-08-08 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
EP3762012A1
(en)
|
2018-03-09 |
2021-01-13 |
Ospedale San Raffaele S.r.l. |
Il-1 antagonist and toxicity induced by cell therapy
|
MA52193A
(fr)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics Inc |
Récepteurs de lymphocytes t et cellules modifiées les exprimant
|
MX2020010461A
(es)
|
2018-04-05 |
2021-01-15 |
Juno Therapeutics Inc |
Linfocitos t que expresan un receptor recombinante, polinucleotidos y metodos relacionados.
|
BR112020020245A2
(pt)
|
2018-04-05 |
2021-04-06 |
Editas Medicine, Inc. |
Métodos de produzir células expressando um receptor recombinante e composições relacionadas
|
MX2021001519A
(es)
|
2018-08-09 |
2021-05-27 |
Juno Therapeutics Inc |
Metodos para valorar acidos nucleicos integrados.
|
MX2021001523A
(es)
|
2018-08-09 |
2021-05-27 |
Juno Therapeutics Inc |
Procesos para generar células modificadas y composiciones de las mismas.
|
KR20210112295A
(ko)
|
2018-08-31 |
2021-09-14 |
잉벡띠스 에스아 |
다수의 hla-g 이소형에 대한 키메라 항원 수용체
|
KR20210098450A
(ko)
|
2018-10-31 |
2021-08-10 |
주노 테라퓨틱스 게엠베하 |
세포의 선택 및 자극을 위한 방법 및 이를 위한 장치
|
CN113646335A
(zh)
|
2018-11-01 |
2021-11-12 |
朱诺治疗学股份有限公司 |
使用对b细胞成熟抗原具有特异性的嵌合抗原受体的治疗的方法
|
AU2019374103A1
(en)
|
2018-11-01 |
2021-05-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
|
BR112021008738A2
(pt)
|
2018-11-06 |
2021-11-03 |
Juno Therapeutics Inc |
Processo para produzir células t geneticamente construídas
|
US20220008465A1
(en)
|
2018-11-16 |
2022-01-13 |
Juno Therapeutics, Inc. |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
SG11202105502RA
(en)
|
2018-11-30 |
2021-06-29 |
Juno Therapeutics Inc |
Methods for treatment using adoptive cell therapy
|
SG11202105380RA
(en)
|
2018-11-30 |
2021-06-29 |
Juno Therapeutics Inc |
Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
|
PE20212198A1
(es)
|
2019-01-29 |
2021-11-16 |
Juno Therapeutics Inc |
Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1)
|
CA3136618A1
(en)
|
2019-04-10 |
2020-10-15 |
Elevatebio Technologies, Inc. |
Flt3-specific chimeric antigen receptors and methods of using the same
|
AU2020265741A1
(en)
|
2019-05-01 |
2021-11-25 |
Editas Medicine, Inc. |
Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
|
WO2020223571A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
BR112021023411A2
(pt)
|
2019-05-22 |
2022-02-01 |
Massachusetts Inst Technology |
Composições e métodos de rna circular
|
CN112390894A
(zh)
|
2019-08-12 |
2021-02-23 |
广东东阳光药业有限公司 |
嵌合抗原受体及其应用
|
AU2020377043A1
(en)
|
2019-10-30 |
2022-06-02 |
Juno Therapeutics Gmbh |
Cell selection and/or stimulation devices and methods of use
|
CN115398231A
(zh)
|
2019-12-06 |
2022-11-25 |
朱诺治疗学股份有限公司 |
与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法
|
JP2023512209A
(ja)
|
2020-01-28 |
2023-03-24 |
ジュノー セラピューティクス インコーポレイテッド |
T細胞形質導入のための方法
|
KR20230009386A
(ko)
|
2020-04-10 |
2023-01-17 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
|
EP4150640A1
(en)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
CA3179423A1
(en)
|
2020-05-19 |
2021-11-25 |
Robert Alexander WESSELHOEFT |
Circular rna compositions and methods
|
KR20230042283A
(ko)
|
2020-06-26 |
2023-03-28 |
주노 테라퓨틱스 게엠베하 |
재조합 수용체를 조건부로 발현하는 조작된 t 세포, 관련된 폴리뉴클레오티드 및 방법
|
WO2022098787A1
(en)
|
2020-11-04 |
2022-05-12 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
US20240168012A1
(en)
|
2021-03-22 |
2024-05-23 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
WO2022234009A2
(en)
|
2021-05-06 |
2022-11-10 |
Juno Therapeutics Gmbh |
Methods for stimulating and transducing t cells
|
CN115404240A
(zh)
|
2021-05-28 |
2022-11-29 |
上海环码生物医药有限公司 |
制备环形rna的构建体、方法及其用途
|
WO2023081735A1
(en)
|
2021-11-03 |
2023-05-11 |
Celgene Corporation |
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
TW202334080A
(zh)
|
2021-11-08 |
2023-09-01 |
美商歐納醫療公司 |
用於遞送環狀聚核苷酸之脂質奈米粒子組合物
|
WO2023164440A1
(en)
|
2022-02-22 |
2023-08-31 |
Juno Therapeutics, Inc. |
Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
WO2023231959A2
(en)
|
2022-05-30 |
2023-12-07 |
Shanghai Circode Biomed Co., Ltd |
Synthetic circular rna compositions and methods of use thereof
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
WO2024031091A2
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
WO2024129778A2
(en)
|
2022-12-13 |
2024-06-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
WO2024129982A2
(en)
|
2022-12-15 |
2024-06-20 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|